Compared with placebo , rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction ( PMI ) and levels of cardiac troponin I ( cTnI ) associated with decreased relative expression of serum miR-@ , levels of inflammatory cytokines ( INF - , TNF - , and IL-@ ) , increased SHIP-@ expression and CD@ ( + ) FoxP@ ( + ) Treg percentage values ( P < @ ) .